CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The CRISPRGlue project aims to develop engineered nanogels for the targeted delivery of CRISPR gene editing tools to treat glioblastoma multiforme, a severe brain cancer. By utilizing ultrasound-triggered release, the project seeks to overcome challenges such as blood-brain barrier penetration and off-target effects, e…
Glioblastoma multiforme (GBM), constituting 50.1% of CNS tumors, is the most frequent malignant brain cancer with a median survival of 14.6 months, highlighting the urgent need for more effective treatment strategies.
The rise of effective gene therapies especially CRISPR/Cas (“clustered regularly interspaced short palindromic repeats/associated protein 9”) based gene editing technology has sparked optimism for treating GBM.
Given the ongoing challenges with CRISPR-Cas gene therapy, such as effe…
UNIVERSIDAD DEL PAIS VASCO/ EUSKAL HERRIKO UNIBERTSITATEA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Spain, Donostia San Sebastian
Type: Research institute
Activity type: Research Organisations
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
